drugset / Trial / NCT00601523
Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The general aim of this study is to obtain long-term safety and tolerability data on pramipexole ER, in daily doses from 0.375mg to 4.5mg once daily (q.d), in patients who have previously completed a pramipexole double-blind study in early PD (248.524(NCT00479401) or 248.636(NCT00558025) trial).
Timeline
- Start
- 2008-01
- Primary completion
- 2010-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pramipexole | Unknown | 0.375 mg | — |
| Comparator | Pramipexole | Unknown | 4.5 mg | — |